Artificial Intelligence (AI) in Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032

Artificial Intelligence (AI) in Diagnostics Market Summary

• The global artificial intelligence in diagnostics market is expected to increase from USD 1,623.20 million in 2024 to USD 8,081.97 million by 2032, reflecting strong and sustained growth.
• The global artificial intelligence in diagnostics market is growing at a CAGR of 22.31% during the forecast period from 2025 to 2032.
• The global artificial intelligence in diagnostics market is witnessing rapid growth, driven by the rising prevalence of chronic, genetic, and infectious diseases. AI technologies facilitate early detection, precise diagnosis, and personalized treatment by analyzing complex medical data and identifying subtle patterns. This growth is further strengthened by increased research and development, strategic collaborations, and continuous product innovation by key market players, accelerating clinical adoption across healthcare settings.
• The leading companies operating in the artificial intelligence in diagnostics market include GE HealthCare, Aidoc, Qure.ai, Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Tecomet Inc., Prenosis, Inc., Riverain Technologies, Envisionit Deep AI (Pty) Ltd., Deep Bio Inc., Inc., and Others.
• North America is expected to remain a dominant force in the artificial intelligence in diagnostics market. This is driven by the increasing burden of chronic diseases such as cancer, lifestyle-related disorders like diabetes, and infectious conditions, including HIV. This growing disease prevalence, combined with a strong healthcare ecosystem, cutting-edge R&D in AI-driven diagnostics, and rapid regulatory approvals, is positioning the U.S. as a global hub for AI-enabled diagnostic innovations.
• In the component segment of the artificial intelligence in diagnostics market, the hardware/software category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of Artificial Intelligence (AI) in Diagnostics Market

• The Rising Cases of Chronic and Genetic Diseases: The increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer, along with the growing incidence of genetic disorders, is driving demand for more accurate and timely diagnostics. AI-powered tools can analyze vast datasets, identify early disease markers, and predict disease progression, helping clinicians provide personalized care. This heightened need for precision and efficiency in managing complex health conditions is significantly boosting the adoption of AI diagnostic solutions across hospitals, laboratories, and research centers.
• Growing focus on research and development initiatives and the formation of strategic partnerships: Healthcare organizations, technology companies, and research institutions are increasingly investing in research and development to advance AI diagnostic capabilities. Strategic collaborations and partnerships are facilitating the co-creation of innovative solutions, clinical validation of AI models, and faster integration of AI into healthcare workflows. These initiatives accelerate product innovation, improve algorithm accuracy, and increase trust among healthcare providers, thereby driving the overall growth of the AI in Diagnostics market.
• Increase in product development activities among the key market players: Key market players are actively expanding their product portfolios by developing new AI-driven diagnostic platforms and enhancing existing solutions. These activities include integrating advanced machine learning algorithms, improving user interfaces, and ensuring compliance with regulatory standards. Continuous product innovation not only attracts new customers but also encourages healthcare providers to upgrade their diagnostic infrastructure, thereby fueling market growth and creating competitive differentiation among leading companies.

Artificial Intelligence (AI) in Diagnostics Market Report Segmentation

This artificial intelligence in diagnostics market report offers a comprehensive overview of the global artificial intelligence in diagnostics market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Component (Hardware/Software and Services), Application (Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and Others), Technology (Machine Learning, Natural Language Processing, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing artificial intelligence in diagnostics market.

Artificial Intelligence (AI) in Diagnostics refers to the use of advanced algorithms, including machine learning and deep learning, to analyze complex medical data and support clinical decision-making. By interpreting medical images, pathology slides, genomic data, and electronic health records, AI enhances diagnostic accuracy, speeds up disease detection, and enables predictive insights. These technologies assist healthcare professionals in identifying abnormalities, personalizing treatment plans, and improving overall patient outcomes, making diagnostics faster, more precise, and more efficient.

The growth of artificial intelligence in diagnostics market is being strongly propelled by several key factors. The rising prevalence of chronic and genetic diseases, including cancer, cardiovascular disorders, and diabetes, is driving demand for accurate, timely, and personalized diagnostics, making AI-powered tools increasingly essential in clinical practice. This is further supported by a growing focus on research and development initiatives and the formation of strategic partnerships between healthcare providers, technology companies, and research institutions, which accelerate innovation, clinical validation, and seamless integration of AI solutions into healthcare workflows.

Additionally, key market players are actively expanding their product portfolios by developing new AI-driven diagnostic platforms and enhancing existing tools with advanced machine learning algorithms, improved user interfaces, and regulatory compliance. Together, these trends are fostering increased adoption of AI diagnostics, improving clinical efficiency, and driving substantial growth in the market.

What are the latest Artificial Intelligence (AI) in Diagnostics Market Dynamics and Trends?

The Artificial Intelligence (AI) in Diagnostics market is expanding rapidly, driven by the rising prevalence of chronic, genetic, and infectious diseases such as cancer, cardiovascular disorders, neurological conditions, diabetes, rare genetic disorders, and infections, including HIV and hepatitis. This growth is further supported by the increasing adoption of digital health and imaging technologies, along with accelerated product development initiatives by key market players worldwide.

Cancer remains one of the primary drivers of market growth. As per Delveinsight analysis, new cancer cases are projected to reach 21.5 million in 2025, rising sharply to 32.5 million by 2045. This surge underscores the urgent demand for AI-enabled diagnostic solutions, particularly in oncology, where AI-powered imaging and pathology tools are proving highly effective in detecting early-stage tumors, accurately grading cancers, and supporting treatment selection. By enhancing diagnostic speed and precision, these tools help reduce errors and improve patient outcomes.

Beyond oncology, the increasing incidence of cardiovascular and metabolic disorders is accelerating AI adoption in diagnostics. Approximately 640 million people worldwide were living with heart and circulatory diseases, with around 67.5 million new cases reported annually. Similarly, an estimated 536.5 million adults had diabetes in recent years, a figure projected to rise to 643.5 million by 2030 and 783.5 million by 2045. Infectious diseases add further pressure: globally, 304 million people were living with hepatitis B and C, while nearly 39.5 million were living with HIV, including 1.5 million children. These statistics highlight the expanding role of AI in enabling earlier detection, real-time monitoring, and individualized disease management across multiple therapeutic areas.

The growing emphasis on precision diagnostics is also reflected in regulatory developments. In 2023, the U.S. FDA approved 16 new personalized therapies for rare disease patients, up from six approvals in 2022, with seven of these focused on oncology. AI complements this trend by analyzing genomic and clinical datasets, identifying disease risks, predicting therapy responses, and guiding the development of targeted treatment regimens.

Taken together, these trends and statistics underscore not only the rising global health burden but also the urgent need for scalable, intelligent healthcare solutions. As AI continues to integrate into diagnostics, its role in enhancing accuracy, accelerating clinical decision-making, and advancing personalized care will deepen. Consequently, the AI in Diagnostics market is poised for substantial expansion during the forecast period of 2025 to 2032, redefining the future of global healthcare delivery.

However, the growth of the global Artificial Intelligence (AI) in Diagnostics market, particularly in the Machine Learning and Oncology segments, faces notable restraints. Data privacy and security concerns remain a critical challenge, as AI systems rely on vast amounts of sensitive patient information, including medical images, genomic data, and electronic health records. Ensuring compliance with data protection regulations and safeguarding against breaches increases operational complexity and may slow adoption. Regulatory hurdles and the need for rigorous clinical validation further constrain growth. AI-driven diagnostic tools, especially those applied in oncology, must undergo extensive testing to demonstrate accuracy, reliability, and clinical utility, which can be time-consuming and costly. These challenges are compounded by the necessity for approval from multiple regulatory bodies across different regions, creating delays in product launches and market penetration. Collectively, concerns over data security and the stringent regulatory landscape limit the full potential of AI in diagnostics, despite its proven ability to enhance early detection, improve workflow efficiency, and support precision medicine initiatives in critical areas such as cancer care.

Artificial Intelligence (AI) in Diagnostics Market Segment Analysis

Artificial Intelligence (AI) in Diagnostics Market by Component (Hardware/Software and Services), Application (Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and Others), Technology (Machine Learning, Natural Language Processing, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Artificial Intelligence (AI) in Diagnostics Market Regional Analysis

North America Artificial Intelligence (AI) in Diagnostics Market Trends

North America, led by the U.S., accounted for a dominant 51% share of the global artificial intelligence in diagnostics market in 2024. The North American artificial intelligence in diagnostics market is experiencing robust growth, driven by the increasing burden of chronic diseases such as cancer, lifestyle-related disorders like diabetes, and infectious conditions, including HIV. This growing disease prevalence, combined with a strong healthcare ecosystem, cutting-edge R&D in AI-driven diagnostics, and rapid regulatory approvals, is positioning the U.S. as a global hub for AI-enabled diagnostic innovations.

According to DelveInsight analysis (2025), the number of new cancer cases in the United States is projected to reach approximately 2,535,766 in 2025, with the national burden expected to rise significantly to around 3,380,124 cases by 2045. With such alarming figures, AI-based diagnostic technologies are increasingly being adopted to enhance early detection, improve accuracy, and personalize treatment strategies by leveraging genomic, imaging, and clinical data.

Infectious diseases are also fueling market demand. Further analysis reported that in 2024 that an estimated 31,800 new HIV infections occurred 2022 across the U.S., underscoring the critical need for advanced diagnostic platforms capable of enabling timely and precise identification.

AI solutions in diagnostics can significantly reduce turnaround times, identify subtle disease markers invisible to the human eye, and act as valuable decision-support tools for clinicians managing high patient volumes. The growing acceptance of such solutions reflects their potential to address major gaps in traditional diagnostic pathways.

Regulatory support further strengthens the market landscape. For instance, in February 2025, Ibex Medical Analytics received FDA 510(k) clearance for its Ibex Prostate Detect platform, an AI-based in vitro diagnostic tool that generates heat maps to detect early and rare forms of prostate cancer.

This approval highlights the FDA's increasing openness toward AI-powered innovations, encouraging further product development and commercialization in the U.S. diagnostic sector. Several leading players in the U.S. are actively shaping the AI in diagnostics space, leveraging their technological expertise and strong industry presence.

Companies such as IBM Watson Health, GE HealthCare, Microsoft (Azure AI for Healthcare), Google Health (DeepMind), and Siemens Healthineers (U.S. operations) are investing heavily in AI platforms that integrate imaging, pathology, and electronic health records to deliver faster and more reliable diagnostic insights.

Startups and specialized companies like PathAI, Freenome, and Tempus are also making significant strides, particularly in oncology diagnostics and precision medicine applications, while partnerships with healthcare providers and research institutes continue to accelerate AI adoption.

Hence, the convergence of rising disease prevalence, robust R&D pipelines, supportive regulatory frameworks, and active participation of global and domestic leaders is anticipated to drive substantial growth in the regional Artificial Intelligence in diagnostics market over the forecast period of 2025 to 2032.

Europe Artificial Intelligence (AI) in Diagnostics Market Trends

The Europe artificial intelligence in diagnostics market is experiencing steady growth, driven by advancements in AI technologies, increasing healthcare digitization, and strong regulatory and policy support across the region. The adoption of AI in medical imaging, pathology, cardiology, and oncology is improving diagnostic accuracy, workflow efficiency, and patient outcomes. Investments in smart hospitals, integrated healthcare IT systems, and AI-enabled diagnostic platforms are facilitating widespread implementation, while European governments and health authorities are promoting AI adoption through funding initiatives, pilot programs, and clear regulatory pathways for AI-based medical devices.

Several insights highlight key trends in the region. First, countries such as Germany, the United Kingdom, and France are leading AI adoption due to advanced healthcare infrastructure, high digital literacy, and favorable reimbursement mechanisms. Second, there is an increasing focus on collaborations between AI startups, established medical technology companies, and academic research institutions to develop clinically validated and regulatory-compliant solutions. Third, there is growing emphasis on explainable AI and ethical frameworks to ensure transparency, trust, and safety in clinical decision-making. Additionally, AI-powered predictive diagnostics, remote monitoring, and digital pathology are gaining traction, helping healthcare providers manage patient care more efficiently and reduce diagnostic delays.

Therefore, Europe is positioning itself as a key market for AI in diagnostics, with technological innovation, strategic partnerships, and supportive regulatory environments driving adoption and improving the quality and accessibility of healthcare services across the region.

Asia-Pacific Artificial Intelligence (AI) in Diagnostics Market Trends

The Asia-Pacific artificial intelligence in diagnostics market is witnessing robust growth, driven by rapid technological advancements, rising healthcare demands, and supportive government initiatives. Integration of AI technologies, such as machine learning and deep learning, is significantly enhancing the accuracy, speed, and efficiency of disease detection, particularly in medical imaging, pathology, and predictive diagnostics. Investment in healthcare infrastructure across the region is facilitating wider adoption of AI-driven diagnostic tools, helping to address the growing burden of chronic diseases and the challenges posed by an aging population. Government policies and incentives are further encouraging integration of AI technologies in clinical practice, promoting research and development, and supporting healthcare providers in deploying innovative diagnostic solutions.

Several insights also highlight the dynamics of the market. First, countries with advanced healthcare systems, such as Australia, Japan, and South Korea, are expected to lead adoption due to better infrastructure, higher digital literacy, and favorable reimbursement policies. Second, emerging economies like India, China, and Southeast Asian nations are rapidly expanding AI applications as they seek cost-effective solutions to improve diagnostic accuracy and reduce patient wait times. Third, the market is seeing a growing trend of collaborations between local hospitals, AI startups, and global technology companies to co-develop region-specific solutions tailored to population health needs. Lastly, AI-powered telemedicine and remote diagnostics are gaining traction, especially in rural and underserved areas, further extending healthcare accessibility.

Hence, the Asia-Pacific region is poised to become a global hub for AI in diagnostics, with innovation, policy support, and strategic partnerships driving both market expansion and improvements in clinical outcomes.

Who are the major players in the Artificial Intelligence (AI) in Diagnostics Market?

The following are the leading companies in the artificial intelligence in diagnostics market. These companies collectively hold the largest market share and dictate industry trends.

• GE HealthCare
• Aidoc
• Qure.ai
• Siemens Healthineers
• PathAI
• Ibex
• Owkin, Inc
• Imagen Technologies
• Aiforia
• RADLogics
• Tecomet Inc.
• Prenosis, Inc.
• Riverain Technologies
• Envisionit Deep AI (Pty) Ltd.
• Deep Bio Inc., Inc.

How is the competitive landscape shaping the Artificial Intelligence (AI) in Diagnostics market?

The competitive landscape of the artificial intelligence in diagnostics market is evolving rapidly, driven by continuous technological advancements, strategic partnerships, and increasing investment in AI-enabled healthcare solutions. The market is moderately concentrated, with a mix of established medical technology firms, global tech giants, and innovative startups competing for leadership. Key players focus on developing more accurate, efficient, and user-friendly diagnostic platforms, often emphasizing deep learning algorithms, cloud-based solutions, and integration with existing hospital information systems. Companies are also forming collaborations with hospitals, research institutions, and technology partners to accelerate product development and clinical validation.

Startups and established firms alike are differentiating themselves through specialized applications in radiology, pathology, cardiology, and oncology diagnostics. The entry of large technology companies further intensifies competition, leading to shorter innovation cycles, more diverse product pipelines, and faster adoption of AI-driven diagnostics across clinical settings.

Hence, the moderately concentrated competitive landscape encourages technological innovation, strategic alliances, and clinical validation, ultimately enhancing diagnostic accuracy, efficiency, and accessibility for healthcare providers and patients.

Recent Developmental Activities in the Artificial Intelligence (AI) in Diagnostics Market

• In April 2025, Roche announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Device Designation to its VENTANA(R) TROP2 (EPR20043) RxDx Device. This represents the first time a computational pathology companion diagnostic (CDx) device has received a Breakthrough Device Designation.
• In April 2025, Avant Technologies, Inc., along with its joint venture partner Ainnova Tech, Inc., announced that the U.S. Food and Drug Administration (FDA) is reviewing its pre-submission package for a meeting concerning Avant's VisionAI platform. The technology is designed to transform early disease detection through artificial intelligence.
• In April 2025, Proprio announced that its Paradigm AI surgical guidance platform had received FDA 510(k) clearance to incorporate intraoperative measurements, allowing the first-ever real-time 3D, dynamic, and segmental visualization and measurement of anatomy during surgery.
• In September 2024, Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, unveiled the latest enhancements to its Ibex-AI platform. Developed in collaboration with pathologists worldwide who use the platform in daily clinical practice, these new features underscore Ibex's commitment to delivering advanced diagnostic tools designed to support healthcare professionals at the forefront of patient care.

Artificial Intelligence (AI) in Diagnostics Market Segmentation

• Artificial Intelligence (AI) in Diagnostics by Component Exposure
• Hardware/Software
• Services
• Artificial Intelligence (AI) in Diagnostics Application Exposure
• Infectious Disease Diagnostics
• Radiology
• Oncology
• Cardiology
• Others
• Artificial Intelligence (AI) in Diagnostics Technology Exposure
• Machine Learning
• Natural Language Processing
• Others
• Artificial Intelligence (AI) in Diagnostics Geography Exposure
• North America Artificial Intelligence (AI) in Diagnostics Market
• United States Artificial Intelligence (AI) in Diagnostics Market
• Canada Artificial Intelligence (AI) in Diagnostics Market
• Mexico Artificial Intelligence (AI) in Diagnostics Market
• Europe Artificial Intelligence (AI) in Diagnostics Market
• United Kingdom Artificial Intelligence (AI) in Diagnostics Market
• Germany Artificial Intelligence (AI) in Diagnostics Market
• France Artificial Intelligence (AI) in Diagnostics Market
• Italy Artificial Intelligence (AI) in Diagnostics Market
• Spain Artificial Intelligence (AI) in Diagnostics Market
• Rest of Europe Artificial Intelligence (AI) in Diagnostics Market
• Asia-Pacific Artificial Intelligence (AI) in Diagnostics Market
• China Artificial Intelligence (AI) in Diagnostics Market
• Japan Artificial Intelligence (AI) in Diagnostics Market
• India Artificial Intelligence (AI) in Diagnostics Market
• Australia Artificial Intelligence (AI) in Diagnostics Market
• South Korea Artificial Intelligence (AI) in Diagnostics Market
• Rest of Asia-Pacific Artificial Intelligence (AI) in Diagnostics Market
• Rest of the World Artificial Intelligence (AI) in Diagnostics Market
• South America Artificial Intelligence (AI) in Diagnostics Market
• Middle East Artificial Intelligence (AI) in Diagnostics Market
• Africa Artificial Intelligence (AI) in Diagnostics Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are transforming the diagnostics landscape by enhancing accuracy, speed, and accessibility in disease detection and management. Advanced algorithms analyze medical imaging, pathology slides, and genomic data with remarkable precision, often identifying abnormalities earlier than traditional methods. In radiology, AI tools assist in detecting tumors, fractures, and cardiovascular anomalies, significantly improving workflow efficiency and reducing diagnostic errors. Similarly, in pathology and oncology, AI platforms enable automated slide interpretation and tumor classification, supporting faster and more consistent clinical decisions.

Beyond imaging, AI applications are expanding into predictive diagnostics and personalized medicine. Machine learning models can forecast disease progression, identify at-risk patients, and tailor treatment strategies based on individual data profiles. Natural language processing is being used to extract valuable insights from electronic health records, helping clinicians make more informed decisions. AI-powered diagnostic chatbots and digital assistants are also improving patient engagement by offering preliminary assessments and guiding care pathways.

Therefore, AI-driven innovations are redefining diagnostics through automation, precision, and data integration. As algorithms continue to learn from larger and more diverse datasets, they are expected to become even more reliable and clinically interpretable, paving the way for truly personalized, data-driven healthcare delivery.

U.S. Tariff Impact Analysis on the Artificial Intelligence (AI) in Diagnostics Market:

U.S. tariffs have a notable impact on the artificial intelligence in diagnostics market by increasing costs and disrupting supply chains. Since AI diagnostic systems depend on imported components such as semiconductors, sensors, and computing hardware, tariffs on these inputs raise production and procurement costs, slowing adoption among healthcare providers. The added financial burden often leads to higher prices for diagnostic services and can delay new product launches or clinical implementations.

Tariffs also create uncertainty in global supply chains, forcing manufacturers to find alternative suppliers or relocate production, which adds further costs and delays. Smaller diagnostic firms are particularly affected due to limited financial flexibility. However, the market is adapting by emphasizing domestic sourcing, cloud-based AI platforms, and software-driven solutions that rely less on imported hardware. While tariffs may temporarily restrain growth, these adjustments are encouraging innovation and supply chain resilience, ultimately strengthening the long-term competitiveness of the U.S. AI diagnostics sector.

How This Analysis Helps Clients

• Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
• Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
• Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
• Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Artificial Intelligence (AI) in Diagnostics market report study

• Market size analysis for the current artificial intelligence in diagnostics market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the artificial intelligence in diagnostics market.
• Various opportunities available for the other competitors in the artificial intelligence in diagnostics market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current artificial intelligence in diagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the artificial intelligence in diagnostics market growth in the future?

Frequently Asked Questions for the Artificial Intelligence (AI) in Diagnostics Market

1. What is the growth rate of artificial intelligence in diagnostics market?

• The artificial intelligence in diagnostics market is estimated to grow at a CAGR of 22.31% during the forecast period from 2025 to 2032.

2. What is the market for artificial intelligence in diagnostics?

• The artificial intelligence in diagnostics market was valued at USD 1,623.20 million in 2024, and is expected to reach USD 8,081.97 million by 2032.

3. Which region has the highest share in the artificial intelligence in diagnostics market?

• North America is expected to remain a dominant force in the artificial intelligence in diagnostics market. This is driven by the increasing burden of chronic diseases such as cancer, lifestyle-related disorders like diabetes, and infectious conditions, including HIV. This growing disease prevalence, combined with a strong healthcare ecosystem, cutting-edge R&D in AI-driven diagnostics, and rapid regulatory approvals, is positioning the U.S. as a global hub for AI-enabled diagnostic innovations.

4. What are the drivers for the artificial intelligence in diagnostics market?

• The global artificial intelligence in diagnostics market is witnessing rapid growth, driven by the rising prevalence of chronic, genetic, and infectious diseases. AI technologies facilitate early detection, precise diagnosis, and personalized treatment by analyzing complex medical data and identifying subtle patterns. This growth is further strengthened by increased research and development, strategic collaborations, and continuous product innovation by key market players, accelerating clinical adoption across healthcare settings.

5. Who are the key players operating in the artificial intelligence in diagnostics market?

• Some of the key market players operating in the artificial intelligence in diagnostics market include GE HealthCare, Aidoc, Qure.ai, Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Tecomet Inc., Prenosis, Inc., Riverain Technologies, Envisionit Deep AI (Pty) Ltd., Deep Bio Inc., Inc., and Others.